A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | MicrobiomeTrials← Back to trialsNCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-02-26Est. Completion: 2027-09-01
Enrollment target: 740 participants Locations- City of Hope, Duarte, California, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee, Florida, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Health Partners Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
- Health Partners Cancer Center at Regions Hospital, Saint Paul, Minnesota, United States
- Washington University, School of Medicine, St Louis, Missouri, United States
- Roswell Park Cancer Institute IDS, Buffalo, New York, United States
- Memorial Sloan Kettering Hospital, New York, New York, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Chris O'Brien Lifehouse, Camperdown, Australia
- Icon Cancer Centre Chermside, Chermside, Australia
Other microbiome trials you might be interested in
Advanced Solid TumorMetastatic Solid Tumor
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine f…
Hamburg, GermanyEst. completion Dec 2026
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell Carcinoma
Monash Medical Centre Clayton, Clayton, AustraliaIcon Cancer Centre Hobart, Hobart, AustraliaIcon Cancer Centre Townsville, Hyde Park, AustraliaCliniques Universitaires Saint-Luc, Brussels, BelgiumUZA, Edegem, BelgiumUniversitair Ziekenhuis Gent, Ghent, BelgiumUniversitair Ziekenhuis Brussel, Jette, BelgiumUZ Leuven, Leuven, BelgiumCross Cancer Institute, Edmonton, Alberta, CanadaSunnybrook Research Institute, Toronto, CanadaPrincess Margaret Cancer Centre, Toronto, CanadaBC Cancer - Vancouver, Vancouver, CanadaWest China Hospital, Sichuan University, Chengdu, ChinaSun Yat-sen University Cancer Center, Guangzhou, ChinaChu Bordeaux, Bordeaux, FranceCentre Georges Franăois Leclerc, Dijon, FranceHopital Claude Huriez - Chu Lille, Lille, FranceCentre Léon Bérard, Lyon, FranceHăpital de La Timone, Marseille, FranceChu Nantes - Hătel Dieu, Nantes, FranceInstitut Claudius Regaud, Toulouse, FranceICL - Alexis Vautrin, Vandœuvre-lès-Nancy, FranceInstitut Gustave Roussy, Villejuif, FranceKrankenhaus Nordwest GmbH, Frankfurt, GermanyBacs-Kiskun Varmegyei Oktatokorhaz, Kecskemét, HungaryHumanitas Gavazzeni, Bergamo, ItalyIRCCS Ospedale Policlinico San Martino, Genova, ItalyAOU Federico II - Oncologia Clinica, Naples, ItalyCentro Ricerche Cliniche di Verona s.r.l., Verona, ItalySaitama Medical University International Medical Center, Hidaka, JapanKanagawa Cancer Center, Kanagawa, JapanNational Cancer Center Hospital East, Kashiwa-shi, JapanNHO Shikoku Cancer Center, Matsuyama, JapanShizuoka Cancer Center, Nagaizumi-cho, JapanAichi Cancer Center Hospital, Nagoya, JapanKindai University Hospital, Osakasayama-shi, JapanNational Cancer Center Hospital, Tokyo, JapanCancer Institute Hospital of JFCR, Tokyo, JapanYokohama City University Medical Center, Yokohama, JapanAmsterdam UMC locatie Vumc, Amsterdam, NetherlandsUniversitair Medisch Centrum Groningen, Groningen, NetherlandsLeids Universitair Medisch Centrum, Leiden, NetherlandsMaastricht University Medical Center, Maastricht, NetherlandsRadboud University Medical Center, Nijmegen, NetherlandsAkershus universitetssykehus, Lørenskog, NorwayHaukeland universitetssjukehus, Lørenskog, NorwayOslo Universitetssykehus HF, Radiumhospitalet, Oslo, NorwayKyungpook National University Chilgok Hospital, Daegu, South KoreaNational Cancer Center, Gyeonggi-do, South KoreaCha Bundang Medical Center, Cha University, Seongnam, South KoreaSeoul National University Bundang Hospital, Seongnam, South KoreaSeoul National University Hospital, Seoul, South KoreaSeverance Hospital, Yonsei University Health System, Seoul, South KoreaAsan Medical Center, Seoul, South KoreaSamsung Medical Center, Seoul, South KoreaHospital Universitari Vall D'Hebron, Barcelona, SpainHospital Clinic de Barcelona, Barcelona, SpainHospital de La Santa Creu I Sant Pau, Barcelona, SpainHospital General Universitario Gregorio Marañon, Madrid, SpainHospital Universitario Ramon Y Cajal, Madrid, SpainHospital Universitario 12 de Octubre, Madrid, SpainHOSPITAL REGIONAL UNIVERSITARIO de MALAGA AVDA., Málaga, SpainHospital Universitario Virgen Macarena, Seville, SpainHospital Clinico Universitario de Valencia, Valencia, SpainKaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TaiwanTaichung Veterans General Hospital, Taichung, TaiwanNational Cheng Kung University Hospital, Tainan, TaiwanNational Taiwan University Hospital, Taipei, TaiwanKoo Foundation Sun Yat-Sen Cancer Center, Taipei, TaiwanTaipei Veterans General Hospital, Taipei, TaiwanChang Gung Memorial Hospital, Taoyuan, TaiwanUniversity Hospital Coventry, Coventry, United KingdomBarts Hospital, London, United KingdomRoyal Free Hospital, London, United KingdomNottingham City Hospital Campus, Nottingham, United KingdomLocally Recurrent Oral Cavity Squamous Cell Carcinoma
Locally Recurrent Oropharyngeal Squamous Cell Carcinoma
Stage II Laryngeal Cancer AJCC v8
Stage II Lip and Oral Cavity Cancer AJCC v8
Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVA Laryngeal Cancer AJCC v8
Stage IVA Lip and Oral Cavity Cancer AJCC v8
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVB Laryngeal Cancer AJCC v8
Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with ca…
Tucson, United StatesEst. completion Feb 1, 2033
Metastatic Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with met…
Duarte, United StatesEst. completion Sep 30, 2030